ZIOPHARM Oncology Inc

Alaunos Therapeutics is a clinical-stage company based in Boston, Massachusetts. The company employs 82 people and generates approximately $6 million in annual revenue. Alaunos Therapeutics specializes in developing T-cell receptor (TCR) therapies for the treatment of cancer. These therapies utilize the company's proprietary, non-viral Sleeping Beauty gene transfer platform and a unique cancer mutation hotspot TCR library. The company's focus targets common tumor-related mutations in key oncogenic genes such as KRAS, TP53, and EGFR. Alaunos Therapeutics differentiates itself through its innovative approach to TCR therapy development. By utilizing the Sleeping Beauty gene transfer platform, the company aims to create safer and more effective treatments compared to conventional methods. Furthermore, its unique TCR library enables the targeting of a broader range of cancer mutations, potentially expanding the reach of its therapies. For more information about Alaunos Therapeutics and its innovative cancer treatments, please visit their website at ziopharm.com.